Supernus Pharma (SUPN) Tops Q2 EPS by 14c, Revenues Miss; Offers FY18 Revenue Outlook Below Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Supernus Announces Second Quarter 2018 Financial Results and Record Quarterly Revenue
August 7, 2018 4:16 PM EDTTotal revenue of $99.5 million, a 31% increase over 2017Net product sales of $97.0 million, a 32% increase over 2017Operating earnings of $35.7 million, a 37% increase over 2017Diluted earnings per share (GAAP) of $0.57, a 78% increase over 2017Completed enrollment in the first SPN-812 Phase III trial (P301), with data expected in the fourth quarter of 2018
ROCKVILLE, Md., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Â - Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today reported record financial results for the second quarter of 2018 and... More
